| Literature DB >> 11433329 |
F O Nestle1, J Banchereau, D Hart.
Abstract
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11433329 DOI: 10.1038/89863
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440